Vitale, C., Falchi, L., ten Hacken, E., Gao, H., Shaim, H., Van Roosbroeck, K., . . . Ferrajoli, A. (2016). Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics. Clin Cancer Res.
Chicago-tyylinen lähdeviittausVitale, Candida, et al. "Ofatumumab and Lenalidomide for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics." Clin Cancer Res 2016.
MLA-viiteVitale, Candida, et al. "Ofatumumab and Lenalidomide for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics." Clin Cancer Res 2016.
Varoitus: Nämä viitteet eivät aina ole täysin luotettavia.